arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Oncology Institute, Inc.

TOI
$5.12 0.00 (0.00%) at close
Industrials ·Services-Offices & Clinics of Doctors of Medicine ·USServices-Offices & Clinics of Doctors of Medicine
27 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Oncology Institute, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $527.5M
Dividend Yield
Revenue Growth 34.6%
Op. Margin -2.9%
ROIC -8.4%
FCF / Share $0.11
Trailing P/E
Price / Book
FCF Yield 2.1%
Debt / Equity -3.21
info Valuation on last close. End-of-day price, Aug 3, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$161.28M
↑ +34.6%
Net Income Profit after all expenses
$-2.49M
↑ +87.3%
Operating Margin Operating profit as % of sales
-2.9%
↑ +35.2% 18th
FCF / Share Free cash flow per share
$0.11
↑ +434.7%
Long-Term Debt Long-term obligations
$79.87M
↑ +1.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
16
Financial Health
66
Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters